Lupin launches triple-combo inhaler for COPD in India
In short
Lupin launched Formoflo-G MDI in India for COPD. It is a fixed-dose inhaler that combines three established therapies and was approved by DCGI.
This matters because it adds a new option for people with COPD in India and strengthens Lupin’s respiratory line. The reporting does not say how many patients will use it or what sales may follow.
What the reporting says
Lupin launched Formoflo-G MDI, a fixed-dose triple-combo inhaler for COPD in India, according to publisher summaries. The product combines three established therapies in a twice-daily inhaler after DCGI approval and is described as an important addition to Lupin’s respiratory portfolio. The immediate consequence is a new treatment option for India’s COPD patients; commercial uptake is not stated.
Why it matters
Lupin launched Formoflo-G MDI in India after DCGI approval, making it a fixed-dose triple-combo inhaler for COPD. The summaries say it combines three established therapies in a twice-daily inhaler and is an important addition to Lupin’s respiratory portfolio. The reporting does not state pricing, launch volumes, or sales expectations. The direct impact is on COPD treatment access and Lupin’s respiratory business.